Acceleris Capital

Power Roll Limited is a company based in Sunderland, United Kingdom, focused on the development, manufacturing, and commercialization of innovative energy storage and generation technologies. Founded in 2012, the company offers a range of products, including supercapacitors, batteries, solar photovoltaic (PV) systems, and barrier films. Power Roll's proprietary solar technology produces ultra-thin, flexible solar PV films in continuous rolls through a rapid, cost-effective process. This approach allows for versatile applications, enhancing energy production in various contexts, including automotive and smart grid systems. The company boasts a robust intellectual property portfolio, comprising 15 patent families across its technologies, highlighting its commitment to innovation and potential disruption in the energy sector.

Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP).

Vertical Future Limited, founded in 2016 and headquartered in London, specializes in vertical farming, producing fruits and vegetables in controlled environments. The company focuses on developing innovative hardware and software technologies to enhance sustainable urban food production and supply systems. By utilizing advanced methods, Vertical Future enables customers to cultivate high-quality, nutrient-rich crops efficiently and sustainably, catering not only to the food industry but also to the pharmaceutical sector.

The Frank Food Company is a social enterprise supporting regional farmers.

ADC Biotechnology Ltd specializes in the development of innovative antibody-drug conjugates (ADCs) aimed at treating cancer. Based in St Asaph, United Kingdom, the company has developed a patented Lock-Release technology that streamlines the purification process for ADCs, significantly reducing the number of steps and associated risks in drug production. In addition to its proprietary technology, ADC Biotechnology offers consultancy and research and development services to support drug developers and manufacturers in overcoming challenges related to conjugation processes. Since its establishment in 2010, the company has focused on delivering faster and more cost-effective solutions in the oncology field, facilitating the advancement of targeted therapies for cancer treatment.

Redag Crop Protection specializes in developing innovative crop protection products, including fungicides, herbicides, insecticides, and nematicides. Utilizing a proprietary method known as the Redox Switch™, the company enhances existing crop protection solutions and identifies new intellectual properties to create effective agrochemicals. This approach not only shortens development cycles but also addresses the urgent need for novel products in the agrochemical sector, as traditional options are increasingly withdrawn due to safety concerns or reduced efficacy from pest resistance. By focusing on sustainable food production, Redag Crop Protection aims to enable farmers to better safeguard their crops from pests, thereby contributing to agricultural innovation and sustainability.

Apex Molecular Ltd is a synthetic chemistry company based in Alderley Edge, United Kingdom, specializing in laboratory-scale chemistry services for the pharmaceutical, biotechnology, and applied chemistry sectors. Established in 2008 and rebranded from YProTech Ltd in 2019, the company offers a range of development services, including high potency synthesis, custom synthesis, and project scale-up. Apex Molecular caters to clients in drug discovery, biotechnology, and agritech, delivering services that are timely, reliable, and cost-effective. By employing a flexible approach to project design, the company aims to assist its clients in managing their project portfolios with minimal risk and time delays.

Redag Crop Protection specializes in developing innovative crop protection products, including fungicides, herbicides, insecticides, and nematicides. Utilizing a proprietary method known as the Redox Switch™, the company enhances existing crop protection solutions and identifies new intellectual properties to create effective agrochemicals. This approach not only shortens development cycles but also addresses the urgent need for novel products in the agrochemical sector, as traditional options are increasingly withdrawn due to safety concerns or reduced efficacy from pest resistance. By focusing on sustainable food production, Redag Crop Protection aims to enable farmers to better safeguard their crops from pests, thereby contributing to agricultural innovation and sustainability.

InvestingZone Limited is an online equity crowdfunding platform based in London, United Kingdom, established in 2012. The platform facilitates fundraising for early-stage and growth companies by connecting them with a broad network of experienced investors. It provides a secure environment for companies to manage their shareholder relationships, obtain votes, and engage with stakeholders. Investors can utilize the platform to build and manage their portfolios, track investment performance, and communicate directly with companies and other shareholders through a messaging service. InvestingZone aims to stimulate entrepreneurship by allowing unlisted companies to present their business cases effectively and access funding from sophisticated investors interested in crowdfunding opportunities. The platform emphasizes the importance of providing a clear value proposition and robust investment plans, while also offering investors essential rights and protections similar to those afforded by traditional venture capital.

Evgen Pharma is a clinical stage drug development company headquartered in Wilmslow, United Kingdom, focused on creating sulforaphane-based medicines for various diseases, particularly cancer and neurological conditions. The company's proprietary technology, Sulforadex, consists of synthetic and stabilized analogues of sulforaphane, a compound recognized for its potential therapeutic benefits. Evgen's lead product, SFX-01, is a synthetic version of sulforaphane that is currently undergoing Phase II clinical trials for metastatic breast cancer and subarachnoid hemorrhage. Additionally, SFX-01 is in preclinical development for multiple sclerosis and is also being studied for its efficacy in treating prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Founded in 2007, Evgen Pharma aims to transform scientific research into commercially viable treatments.

EveryCloud Technologies, founded in 2009 and headquartered in San Jose, California, specializes in network management software with a focus on email security. The company filters over 300 million emails monthly for more than 2,000 organizations across 13 countries. With a commitment to customer protection and support, EveryCloud combines responsive service with advanced technology, which has positioned it as a leader in the industry. The company has been recognized as the highest-rated hosted spam filtering vendor on Spiceworks, reflecting positive feedback from its users. EveryCloud operates five data centers globally and provides expert guidance throughout the customer journey, from setup to renewal, facilitated by dedicated account managers and support representatives.

Redag Crop Protection specializes in developing innovative crop protection products, including fungicides, herbicides, insecticides, and nematicides. Utilizing a proprietary method known as the Redox Switch™, the company enhances existing crop protection solutions and identifies new intellectual properties to create effective agrochemicals. This approach not only shortens development cycles but also addresses the urgent need for novel products in the agrochemical sector, as traditional options are increasingly withdrawn due to safety concerns or reduced efficacy from pest resistance. By focusing on sustainable food production, Redag Crop Protection aims to enable farmers to better safeguard their crops from pests, thereby contributing to agricultural innovation and sustainability.

Reacta Biotech has been established to develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards of Good Manufacturing Practice (GMP).

Redx Pharma is a UK-based biotechnology company founded in 2010, specializing in drug discovery and development for oncology and fibrotic diseases. The company focuses on creating novel small molecule drugs aimed at addressing significant unmet medical needs. Its product pipeline includes several promising candidates such as RXC004, a porcupine inhibitor in Phase I clinical development for various cancers; ROCK2, targeting diabetic nephropathy and idiopathic pulmonary fibrosis; and RXC005, a reversible inhibitor of Bruton’s tyrosine kinase. Additionally, Redx Pharma collaborates with global pharmaceutical companies, including a research partnership with Jazz Pharmaceuticals to explore drug candidates targeting the Ras/Raf/MAP kinase pathway. The company operates through subsidiaries dedicated to oncology, anti-infectives, and immunology, generating revenue from scientific programs and research collaborations.

Metronet (UK) is the fastest growing connectivity provider, delivering industry-leading performance and support. Metronet (UK) provides a genuinely unique suite of solutions for businesses that need flexibility, scalability and excellence in customer service.

ADC Biotechnology Ltd specializes in the development of innovative antibody-drug conjugates (ADCs) aimed at treating cancer. Based in St Asaph, United Kingdom, the company has developed a patented Lock-Release technology that streamlines the purification process for ADCs, significantly reducing the number of steps and associated risks in drug production. In addition to its proprietary technology, ADC Biotechnology offers consultancy and research and development services to support drug developers and manufacturers in overcoming challenges related to conjugation processes. Since its establishment in 2010, the company has focused on delivering faster and more cost-effective solutions in the oncology field, facilitating the advancement of targeted therapies for cancer treatment.

Femeda Ltd. is a UK-based company that specializes in developing and manufacturing medical devices aimed at treating female urinary incontinence. Founded in 2002 and located in Cramlington, Femeda focuses on its flagship product, Pelviva, which employs electrostimulation to strengthen pelvic floor muscles and proactively address bladder leakage. The company’s research and development efforts are grounded in understanding the needs of women affected by incontinence, with the goal of creating effective solutions that enhance their quality of life. Pelviva is positioned as a significant technological advancement for women experiencing issues related to weak pelvic floor muscles. Femeda has garnered support from a dedicated group of investors to advance its research initiatives, paving the way for the product's market introduction.

MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in the development of innovative medical devices. The company has created CoagMax, a point-of-care monitor that enables patients to conduct PT/INR testing at home, facilitating self-monitoring of blood coagulation levels. This device utilizes advanced micro electro mechanical sensors embedded in a disposable smart strip, allowing for a convenient, safe, and accurate testing experience. By focusing on patient-friendly solutions, MicroVisk aims to improve the quality of life for individuals requiring regular blood coagulation monitoring.